Fernando Gallardo

Dr. Fernando Gallardo


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JSJuan Sandoval
Juan Sandoval
ADAngel Díaz-Lagares
Angel Díaz-Lagares
RSRocío Salgado
Rocío Salgado
OSOctavio Servitje
Octavio Servitje
Fina ClimentFina Climent
Fina Climent
FGFernando Gallardo
Fernando Gallardo

14 October 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
GDGustavo Deza
Gustavo Deza
JNJaime Notario
Jaime Notario
ALAnna Lopez‐Ferrer
Anna Lopez‐Ferrer
EVEva Vilarrasa
Eva Vilarrasa
MFMarta Ferran
Marta Ferran
FGFernando Gallardo
Fernando Gallardo

1 December 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
FGFernando Gallardo
Fernando Gallardo
JSJuan Sandoval
Juan Sandoval
ADAngel Díaz-Lagares
Angel Díaz-Lagares
RGRicard Garcia
Ricard Garcia
TDTeresa D'ALtri
Teresa D'ALtri
Lluis EspinosaLluis Espinosa
Lluis Espinosa

1 August 2017 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
IGIgnacio Gómez-Martín
Ignacio Gómez-Martín
SMSara Moreno
Sara Moreno
EAEvelyn Andrades-López
Evelyn Andrades-López
IHInma Hernández-Muñoz
Inma Hernández-Muñoz
FGFernando Gallardo
Fernando Gallardo
SSSonia Segura
Sonia Segura
Pigmented facial macules (PFMs) are commonly evaluated in clinical practice, especially in elderly patients with sun-damaged skin. In this clinical setting, one must distinguish benign PFMs from lentigo maligna (LM) or lentigo maligna melanoma (LMM). Dermoscopy has provided some help in this scenario.1-5 However, some of these lesions exhibit overlapping features,4 and classical dermoscopic LM criteria may not be useful to detect early facial melanomas.

22 February 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
FGFernando Gallardo
Fernando Gallardo
JBJoan Bertran
Joan Bertran
ELErika López-Arribillaga
Erika López-Arribillaga
JGJéssica González
Jéssica González
SMSilvia Menéndez
Silvia Menéndez
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). Molecular events leading to CTCL progression are heterogeneous, however recent DNA and RNA sequencing studies highlighted the importance of NF-κB and β-catenin pathways. We here show that the kinase TAK1, known as essential in B-cell lymphoma, is constitutively activated in CTCL cells, but tempered by the MYPT1/PP1 phosphatase complex. Blocking PP1 activity, both pharmacologically and genetically, resulted in TAK1 hyperphosphorylation at residues T344, S389, T444, and T511, which have functional impact on canonical NF-κB signaling. Inhibition of TAK1 precluded NF-κB and β-catenin signaling and induced apoptosis of CTCL cell lines and primary Sézary syndrome cells both in vitro and in vivo. Detection of phosphorylated TAK1 at T444 and T344 is associated with the presence of lymphoma in a set of 60 primary human samples correlating with NF-κB and β-catenin activation. These results identified TAK1 as a potential biomarker and therapeutic target for CTCL therapy.

5 November 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MAMíriam Almirall
Míriam Almirall
JRJesús Rodriguez
Jesús Rodriguez
LMLourdes Mateo
Lourdes Mateo
JCJosé Manuel Carrascosa
José Manuel Carrascosa
JNJaime Notario
Jaime Notario
FGFernando Gallardo
Fernando Gallardo